Blog

RSS Feed
Posted by Michael Wonder on 05 Sep 2016

EMA publishes EPAR for Aerivio Spiromax

5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...

Read more →
Posted by Michael Wonder on 19 Aug 2016

European Commission grants marketing authorisation for Teva’s Cinqaero (reslizumab)

18 August 2016 - First intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma now approved in Europe. ...

Read more →
Posted by Michael Wonder on 26 Jun 2016

Teva receives CHMP positive opinion for Cinqaero (reslizumab)

24 June 2016 - Add-on therapy targeting IL-5 in adults with severe eosinophilic asthma pending marketing authorization in Europe. ...

Read more →